Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). / Eiberg, H; Hansen, L; Korbo, L; Nielsen, Inge-Merete; Svenstrup, K; Bech, S; Pinborg, Lh; Friberg, L; Hjermind, LE; Olsen, Or; Nielsen, Jørgen Erik.

I: Clinical Genetics, Bind 82, Nr. 3, 11.2012, s. 256-63.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Eiberg, H, Hansen, L, Korbo, L, Nielsen, I-M, Svenstrup, K, Bech, S, Pinborg, L, Friberg, L, Hjermind, LE, Olsen, O & Nielsen, JE 2012, 'Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9)', Clinical Genetics, bind 82, nr. 3, s. 256-63. https://doi.org/10.1111/j.1399-0004.2011.01745.x

APA

Eiberg, H., Hansen, L., Korbo, L., Nielsen, I-M., Svenstrup, K., Bech, S., Pinborg, L., Friberg, L., Hjermind, LE., Olsen, O., & Nielsen, J. E. (2012). Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). Clinical Genetics, 82(3), 256-63. https://doi.org/10.1111/j.1399-0004.2011.01745.x

Vancouver

Eiberg H, Hansen L, Korbo L, Nielsen I-M, Svenstrup K, Bech S o.a. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). Clinical Genetics. 2012 nov.;82(3):256-63. https://doi.org/10.1111/j.1399-0004.2011.01745.x

Author

Eiberg, H ; Hansen, L ; Korbo, L ; Nielsen, Inge-Merete ; Svenstrup, K ; Bech, S ; Pinborg, Lh ; Friberg, L ; Hjermind, LE ; Olsen, Or ; Nielsen, Jørgen Erik. / Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). I: Clinical Genetics. 2012 ; Bind 82, Nr. 3. s. 256-63.

Bibtex

@article{e95efd48398246e092be83bfa857efbe,
title = "Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9)",
abstract = "Eiberg H, Hansen L, Korbo L, Nielsen IM, Svenstrup K, Bech S, Pinborg LH, Friberg L, Hjermind LE, Olsen OR, Nielsen JE. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). Kufor-Rakeb syndrome (KRS) is a rare autosomal recessive inherited juvenile parkinsonian syndrome caused by mutations in ATP13A2. We describe six patients from a consanguineous Greenlandic Inuit family, homozygous for a novel frame-shift mutation in exon 22 of ATP13A2 (c.2473C>AA, p.Leu825AsnfsX32). Disease onset varied from 10 to 29 years of age, the latest reported, and the clinical features were highly variable within a wide spectrum of an extrapyramidal-pyramidal syndrome with cognitive/psychiatric features. Ataxia was seen in two patients and axonal neuropathy in one, features not previously related to KRS. Dopamine transporter scans showed symmetrical, severely reduced uptake in striatum in two patients. Magnetic resonance imaging was without atrophy in one patient despite disease duration of 17 years, and cerebral and cerebellar atrophy was seen in another patient after 4 years of disease duration. The molecular pathogenic mechanisms of ATP13A2 mutations are discussed. The observation that the mutant transcript is not degraded by nonsense-mediated RNA decay and the fact that none of the eight heterozygous carriers from the family have KRS symptoms suggest that the mutant protein does not interfere and destroy the function of the wild-type ATP13A2 protein.",
author = "H Eiberg and L Hansen and L Korbo and Inge-Merete Nielsen and K Svenstrup and S Bech and Lh Pinborg and L Friberg and LE Hjermind and Or Olsen and Nielsen, {J{\o}rgen Erik}",
note = "{\textcopyright} 2011 John Wiley & Sons A/S.",
year = "2012",
month = nov,
doi = "10.1111/j.1399-0004.2011.01745.x",
language = "English",
volume = "82",
pages = "256--63",
journal = "Clinical Genetics",
issn = "0009-9163",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9)

AU - Eiberg, H

AU - Hansen, L

AU - Korbo, L

AU - Nielsen, Inge-Merete

AU - Svenstrup, K

AU - Bech, S

AU - Pinborg, Lh

AU - Friberg, L

AU - Hjermind, LE

AU - Olsen, Or

AU - Nielsen, Jørgen Erik

N1 - © 2011 John Wiley & Sons A/S.

PY - 2012/11

Y1 - 2012/11

N2 - Eiberg H, Hansen L, Korbo L, Nielsen IM, Svenstrup K, Bech S, Pinborg LH, Friberg L, Hjermind LE, Olsen OR, Nielsen JE. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). Kufor-Rakeb syndrome (KRS) is a rare autosomal recessive inherited juvenile parkinsonian syndrome caused by mutations in ATP13A2. We describe six patients from a consanguineous Greenlandic Inuit family, homozygous for a novel frame-shift mutation in exon 22 of ATP13A2 (c.2473C>AA, p.Leu825AsnfsX32). Disease onset varied from 10 to 29 years of age, the latest reported, and the clinical features were highly variable within a wide spectrum of an extrapyramidal-pyramidal syndrome with cognitive/psychiatric features. Ataxia was seen in two patients and axonal neuropathy in one, features not previously related to KRS. Dopamine transporter scans showed symmetrical, severely reduced uptake in striatum in two patients. Magnetic resonance imaging was without atrophy in one patient despite disease duration of 17 years, and cerebral and cerebellar atrophy was seen in another patient after 4 years of disease duration. The molecular pathogenic mechanisms of ATP13A2 mutations are discussed. The observation that the mutant transcript is not degraded by nonsense-mediated RNA decay and the fact that none of the eight heterozygous carriers from the family have KRS symptoms suggest that the mutant protein does not interfere and destroy the function of the wild-type ATP13A2 protein.

AB - Eiberg H, Hansen L, Korbo L, Nielsen IM, Svenstrup K, Bech S, Pinborg LH, Friberg L, Hjermind LE, Olsen OR, Nielsen JE. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). Kufor-Rakeb syndrome (KRS) is a rare autosomal recessive inherited juvenile parkinsonian syndrome caused by mutations in ATP13A2. We describe six patients from a consanguineous Greenlandic Inuit family, homozygous for a novel frame-shift mutation in exon 22 of ATP13A2 (c.2473C>AA, p.Leu825AsnfsX32). Disease onset varied from 10 to 29 years of age, the latest reported, and the clinical features were highly variable within a wide spectrum of an extrapyramidal-pyramidal syndrome with cognitive/psychiatric features. Ataxia was seen in two patients and axonal neuropathy in one, features not previously related to KRS. Dopamine transporter scans showed symmetrical, severely reduced uptake in striatum in two patients. Magnetic resonance imaging was without atrophy in one patient despite disease duration of 17 years, and cerebral and cerebellar atrophy was seen in another patient after 4 years of disease duration. The molecular pathogenic mechanisms of ATP13A2 mutations are discussed. The observation that the mutant transcript is not degraded by nonsense-mediated RNA decay and the fact that none of the eight heterozygous carriers from the family have KRS symptoms suggest that the mutant protein does not interfere and destroy the function of the wild-type ATP13A2 protein.

U2 - 10.1111/j.1399-0004.2011.01745.x

DO - 10.1111/j.1399-0004.2011.01745.x

M3 - Journal article

C2 - 21696388

VL - 82

SP - 256

EP - 263

JO - Clinical Genetics

JF - Clinical Genetics

SN - 0009-9163

IS - 3

ER -

ID: 38430884